Panel

Information on Panel composition and the Conflict of Interest Policy can be found in Methods Table 1; financial relationships between Panel members and commercial firms are listed in the Disclosure Table.

Chairs

Harvard Medical School
Duke University School of Medicine
Durham VA Medical Center
Harvard Medical School
College of Medicine, Mayo Clinic

Panel Members

University of Chicago Medical Center
Veterans Affairs Long Beach Healthcare System
University of California Los Angeles
ID Care
Intermountain Medical Center
University of California San Francisco
Johns Hopkins University School of Medicine
Harm Reduction Coalition
University of Michigan Medical School
Rush University Medical Center
Bach and Godofsky, Infectious Diseases
Hospital of the University of Pennsylvania
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Project Inform
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
The University of Alabama at Birmingham
University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Hepatitis and Liver Clinic
University of Washington
Division of Infectious Diseases
Institute of Human Virology/University of Maryland
Treatment Action Group
Boston University School of Medicine
University of California San Francisco
Weill Cornell Medical College
Tufts University School of Medicine
University of Miami School of Medicine
University of California San Diego

*Individual employees of the National Institutes of Health (NIH) have participated in the planning and development of the Guidance, although the NIH is not an official sponsor.

**The views expressed by the participants do not necessarily represent the opinions of the Centers for Disease Control and Prevention, the National Institutes of Health, or the Department of Health and Human Services.

+ Non-voting Panel members

Previous Panel Chairs

Gary L. Davis, MD
Baylor University Medical Center (retired)
2013-2015
Michael S. Saag, MD
The University of Alabama at Birmingham
2013-2015
Donald M. Jensen, MD
University of Chicago Medical Center (retired)
2013-2014
David L. Thomas, MD, MPH
The Johns Hopkins University School of Medicine
2013-21015
Henry Masur, MD* **
National Institutes of Health
2013-2015

Previous Panel Members

Jordan J. Feld, MD, MPH
Toronto Western Hospital Liver Center
2013-2015
Robert T. Schooley, MD
University of California San Diego
2013-2015
Marc G. Ghany, MD* **
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
2013-2015
Kenneth E. Sherman, MD, PhD
University of Cincinnati College of Medicine
2013-2015
Camilla S. Graham, MD, MPH
TREK Therapeutics, PBC
2014-2015
Mark S. Sulkowski, MD
The Johns Hopkins University School of Medicine
2013-2015
Kiren Mitruka, MD, MPH** +
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013-2015
John W. Ward, MD** +
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013-2015

Contributors and Technical Advisors

Saleem Kamili, PhD**
Division of Viral Hepatitis
Deputy Chief, Laboratory Branch, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
For contributing to development of the Testing and Linkage to Care Table 1: FDA-approved, Commercially Available Anti-HCV Screening Assays
Judith Welsh, BS, MLS* **
Clinical Informationist
NIH Library
National Institutes of Health
For performing comprehensive literature searches to identify the evidence used to prepare the Guidance
Rachel J. Wilson**
Division of Viral Hepatitis
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
For comprehensive copy editing and styling of the final Guidance

HCV Guidance Project Management

Sheila A. Tynes, MHA
Program Director
Vincent Keane
Website Publication and Management

Acknowledgement

The International Antiviral Society–USA (IAS–USA) served as the collaborating partner for the HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C from the project’s inception in mid- 2013 through 2015. IAS-USA was responsible for managing the writing panel and the guidance development process. A representative from IAS–USA also served as a co-chair of the HCV Guidance Panel. Due to priorities related to their core mission, IAS-USA elected to end their relationship as collaborating partner on December 31. AASLD and IDSA recognize IAS-USA’s tremendous contribution to the HCV Guidance and the creation and maintenance of www.hcvguidelines.org. Special appreciation is extended to the following individuals for their outstanding service:

  • Michael Saag, MD
  • Donna Jacobsen
  • Cindy Downing
  • Michelle Valderama
  • Jennezel Peneda
  • Rachel Lastra